Pulmatrix, Inc. (Nasdaq: PULM) Resting After Massive Gains

Pulmatrix, Inc. – Nasdaq: PULM

Pulmatrix shares have had quite a ride recently. In mid-January PULM, traded on the Nasdaq, were traing below $1. Yesterday they traded over $6 and are now down to $4.87 in early trading on volumes near 10 million – average daily volume is just under three million.

Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases. Three days ago the company announced that it has entered into a definitive agreement with institutional investors to purchase approximately $5.0 million of shares of common stock in a registered direct offering. That temporarily halted the stock’s rapid rise on dilution worries.

Pulmatrix first reported sales in 2015 and posted a figure of $1.2 million. Since 2011 PULM shares have experienced negative EPS. In 2014 PULM lost $3.47 per share, and in 2015 the company posted an EPS loss of $3.24. No firms or analysts follow shares of PULM.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/3/2017
Ticker Symbol PULM
Last Price a/o 11:12 AM EST  $                    13.26
Average Volume                2,940,000
Market Cap (mlns)  $                    74.92
Sales (mlns) $1.00
Shares Outstanding (mlns) 14.69
Share Float (mlns) 13.19
Shortable No
Optionable No
Inside Ownership 26.44%
Short Float 0.15%
Short Interest Ratio 0.01
Quarterly Return 325.00%
YTD Return 764.41%
Year Return 82.14%

Cerulean Pharma (Nasdaq: CERU) Shares Rise on Sale Speculation

Cerulean Pharma, Inc. – Nasdaq: CERU

An announcement by the Board of Cerulean Pharma to explore strategic alternatives has sent shares higher on speculation that a sale may be in the works. CERU, traded on the Nasdaq under ticker CERU, ended trading Thursday at $0.93 and have reached a high of $1.49 in early trading on heavy volumes. The announcement was likely due to a Phase 2 clinical trial failure, in August, which led to Cerulean cutting half its workforce.

Waltham, MA-based Cerulean Pharma develops products to improve treatment options for cancer victims. The company developed the Dynamic Tumor Targeting™ Platform designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Cerulean’s lead platform-generated NDC clinical candidate, CRLX101, is in multiple clinical trials. Our lead indication is ovarian cancer. Our second platform-generated NDC clinical candidate, CRLX301, is in Phase 2a clinical development for the treatment of advanced solid tumors.

Cerulean sales peaked in 2012 when the company posted a figure of $600k. No sales were reported for 2015. CERU shares have never experienced positive EPS – losing more than $1.20 EPS in each of the past five years. CERU lost $1.56 EPS in 2015. Three firms rate CEU shares. One rates them as a “Strong Buy”, and the other rates CERU as a “Hold”. Their consensus price target is $1.50.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/3/2017
Ticker Symbol CERU
Last Price a/o 9:23 AM EST  $                      1.34
Average Volume                    328,570
Market Cap (mlns)  $                    25.49
Sales (mlns)
Shares Outstanding (mlns) 27.38
Share Float (mlns) 24.66
Shortable Yes
Optionable Yes
Inside Ownership 1.30%
Short Float 2.68%
Short Interest Ratio 2.01
Quarterly Return 24.82%
YTD Return 31.46%
Year Return -58.99%

Naked Brand Group (Nasdaq: NAKD) Rockets on News

Naked Brand Group, Inc. – Nasdaq: NAKD

Naked Brand Group shares, traded on the Nasdaq under ticker NAKD, were up over 180% ($3.34) in the after-hours market from Wednesday’s close ($1.17), but are slightly down in Friday’s early morning trading ($3.29). Thursday volumes were extraordinary – over 17 million shares were traded against an average daily volume of just over 580k.

Catalyst for the price gain appears to be news that the launch of its product line “Comfortably You” will be airing on The Home Shopping Network today. New York, NT-based Naked Brand Group Inc. designs, manufactures, and sells men’s and women’s underwear, intimate apparel, loungewear, and sleepwear products in the United States and Canada. Bare Naked Group products are available on their ecommerce website, Amazon.com, as well as brick & mortar retailers such as Nordstrom, Bloomingdale’s, Dillard’s, Soma, and Saks Fifth Avenue.

Naked Brand Group sales more than doubled from 2015 to 2016 – $600k to $$1.4 million. NAKD shares have had negative EPS every year since 2012 when the company posted a loss of $0.11. In 2015 the EPS loss was $23.33, and in 2016 NAKD EPS posted a loss of $10.13. No analysts follow NAKD.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/3/2017
Ticker Symbol NAKD
Last Price a/o 7:09 AM EST  $                      3.29
Average Volume                    581,600
Market Cap (mlns)  $                    22.66
Sales (mlns) $1.70
Shares Outstanding (mlns) 8.15
Share Float (mlns) 6.97
Shortable Yes
Optionable No
Inside Ownership 12.30%
Short Float 0.15%
Short Interest Ratio 0.02
Quarterly Return 152.73%
YTD Return 178.00%
Year Return 3.21%

Pixelworks Inc. (Nasdaq: PXLW) Reports Earnings and Shares Gain 20%+

Pixelworks, Inc. – Nasdaq: PXLW

Pixelworks shares, traded on the Nasdaq under ticker PXLW, are up over 20% in the after-hours market after the company released 4th quarter financials. PXLW EPS came in at $0.04 which beat estimates by $0.03. Revenues increased 18.6% year-on-year and the $15.99 figure beat estimates by $0.5 million.

San Jose, CA-based Pixelworks develops and markets video display processing technology for high quality digital video applications. It also has an intellectual property portfolio of 135 patents related to the visual display of digital image data.

Sales have been inconsistent but trend lower overall. In 2011 Pixelworks reported sales of $64.6 million and that number declined to $59.5 million in 2015. PXLW shareholders have experienced negative EPS since 2011. And in 2015 EPS for PXLW was a loss of $0.42. Four firms follow Pixelworks. Two rate PXLW shares as a “Strong Buy”, one rates the shares as a “Buy”, and one rates PXLW shares as a “Hold. Their consensus price target is $3.65.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/2/2017
Ticker Symbol PXLW
Last Price a/o 5:44 PM EST  $                      3.70
Average Volume                    184,850
Market Cap (mlns)  $                    89.99
Sales (mlns) $50.90
Shares Outstanding (mlns) 28.66
Share Float (mlns) 23.92
Shortable Yes
Optionable Yes
Inside Ownership 1.40%
Short Float 3.46%
Short Interest Ratio 4.47
Quarterly Return 19.85%
YTD Return 12.14%
Year Return 124.29%

Deckers Corp. (Nasdaq: DECK) Announces Earnings – Shares Down 20%+

Deckers Outdoor Corporation – NYSE: DECK

Deckers Outdoor Corporation announced financial results for the 4th quarter of 2016. EPS missed by $0.11 ($4.11 vs $4.22), revenues missed by almost $29 million ($760.3 vs $789.1), and EPS guidance was lowered from $3.55 to $3.45. Shares, traded on the Nasdaq under ticker DECK, in the after-hours market are down over 25%.

Dave Powers, President and CEO, said “While we are disappointed that our overall results fell short of projections, we are confident that our product, pricing and distribution strategies will benefit the long-term health of the UGG brand,”. Deckers Corporation attempts to build niche brands into global lifestyle leaders through innovative. Brands under the Decker Corporation include UGG footwear, Sanuk, Teva, Hoka One, and Koolaburra. Deckers Corporation operates 153 retail stores.

Sales for Deckers has been flat for the last three years. In 2014 they reported sales of $1.85 Billion and in 2016 the company reported $1.88 Billion. Fourteen firms follow Deckers Corporation. Six rate DECK as a “Strong Buy”, seven rate the shares as a “Hold”, and one rates DECK shares as a “Sell”. Their consensus price target is $61.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/2/2017
Ticker Symbol DECK
Last Price a/o 5:15 PM EST  $                    42.59
Average Volume                    757,250
Market Cap (mlns)  $              1,780.00
Sales (mlns) $1,830.00
Shares Outstanding (mlns) 32.09
Share Float (mlns) 31.79
Shortable Yes
Optionable Yes
Inside Ownership 1.80%
Short Float 14.90%
Short Interest Ratio 6.25
Quarterly Return 8.60%
YTD Return 0.27%
Year Return 10.84%

FireEye, Inc. (Nasdaq: FEYE) Posts Financial Results and Shares Drop

FireEye, Inc. – Nasdaq: FEYE

Security software firm FireEye lost $61.5 million on $184.7 in revenues for the fourth quarter ended December 31, 2016. Shares, traded on the Nasdaq under ticker FEYE, responded by losing almost 20% in after-hours trading on heavy volume. The $0.03 EPS loss beat street estimates but that news was tempered by shrinking margins.

Milpitas, CA-based FireEye invented a virtual machine-based security platform that provides real-time threat protection against cyber attacks. The FireEye Threat Prevention Platform provides real-time, dynamic threat protection without the use of signatures to protect an organization across the primary threat vectors and across the different stages of an attack life cycle.

In 2011, FireEye reported sales of $33.7 million but that figure grew to $623 million by 2015. Shareholders of FEYE have not been rewarded by that sales growth. Shares have tumbled in the last few years and EPS has been negative since 2011 when the company posted an EPS loss of $1.99. In 2015 FEYE shareholders experienced a $3.50 loss. Twenty-three firms follow FireEye. Fifteen rate FEYE as a “Hold”, one rates the shares as a “Sell”, and seven rate FEYE as a “Strong Buy”. Their consensus price target is $15.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/2/2017
Ticker Symbol FEYE
Last Price a/o 5:00 PM EST  $                    10.68
Average Volume                                 4,400,000
Market Cap (mlns)  $              2,250.00
Sales (mlns) $714.20
Shares Outstanding (mlns) 171.1
Share Float (mlns) 154.08
Shortable Yes
Optionable Yes
Inside Ownership 4.50%
Short Float 13.60%
Short Interest Ratio 4.7
Quarterly Return 13.17%
YTD Return 10.50%
Year Return -5.60%

Keryx Therapeutics (Nasdaq: KERX) Up over 15% on Heavy Volume

Keryx Biopharmaceuticals Inc. – Nasdaq: KERX

Boston, MA-based Keryx Pharmaceuticals are up over 15% on heavy volume and have gained almost 40% in the last year. KERX, traded on the Nasdaq, has an average daily volume of 1.58 million but have already traded over 2.5 million at the time of this writing.

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines that provide treatments to people with renal disease. In September 2014, the U.S. Food and Drug Administration approved Keryx’s first medicine, Auryxia tablets.

On January 12th, the company announced the publication of results from its pivotal Phase 3 study evaluating ferric citrate for iron deficiency anemia in non-dialysis-dependent chronic kidney disease in the online issue of the Journal of the American Society of Nephrology.

“The results shown in this pivotal study demonstrated that ferric citrate, if approved for this indication, could provide an important new treatment option for people living with chronic kidney disease and iron deficiency anemia who are not on dialysis,” said Steven Fishbane, M.D., chief of nephrology for North Shore University Hospital and Long Island Jewish Medical Center.

Keryx Biopharmaceuticals sales have increased each year since 2013 and posted a figure of $13.7 million in 2015. KERX shareholders have not experienced the same increase in their EPS. KERX EPS has been negative for the past five years and in 2015 KERX had an EPS loss of $1.19. Eight firms follow Keryx and five rate KERX shares as a “Hold”, one rates it as a “Buy”, and two rate KERX shares as a “Strong Buy”. Their consensus price target is $7.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/2/2017
Ticker Symbol KERX
Last Price a/o 2:33 PM EST  $                      5.39
Average Volume                1,580,000
Market Cap (mlns)  $                  506.49
Sales (mlns) $28.20
Shares Outstanding (mlns) 105.96
Share Float (mlns) 101.78
Shortable Yes
Optionable Yes
Inside Ownership 0.69%
Short Float 20.54%
Short Interest Ratio 13.21
Quarterly Return 5.99%
YTD Return -18.43%
Year Return 38.95%

Benitec Biopharma (Nasdaq: BNTC) Doubles!

Benitec Biopharma Limited – Nasdaq: BNTC

Shares of Benitec Bipharma are more than double yesterday’s closing price and surged to an inter-day high of $4.44 before settling down to $3.50 in mid-day trading. BNTC, traded on the Nasdaq, shares normally have an average daily volume of less than 200k, but today more than seven million shares have traded almost two hours before market close.

The Australian-based company gave a business update on its ddRNAi technology for the development of therapeutics for the treatment of ocular diseases. Benitec Biopharma is a biotechnology company developing a proprietary therapeutic technology platform that combines gene silencing and gene therapy with a goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration. Benitec Biopharma is using DNA-directed RNA interference, or ddRNAi, to develop a pipeline of product candidates for the treatment of several chronic and life-threatening human diseases, such as hepatitis B, age-related macular degeneration, or AMD and oculopharyngeal muscular dystrophy, or OPMD.

Benitec Biopharma has no reported sales. BNTC has no EPS. Only one firm rates BNTC shares it gives it a rating of “Hold”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/2/2017
Ticker Symbol BNTC
Last Price a/o 1:28 PM EST  $                      3.45
Average Volume                    176,560
Market Cap (mlns)  $                  234.45
Sales (mlns) $7.19
Shares Outstanding (mlns) 146.53
Share Float (mlns) 5.49
Shortable Yes
Optionable No
Inside Ownership
Short Float 0.49%
Short Interest Ratio 0.15
Quarterly Return 7.53%
YTD Return 4.58%
Year Return -54.29%

Stemline Therapeutics (Nasdaq: STML) May Face Lawsuit

Stemline Therapeutics Inc. – Nasdaq: STML

Stemline Therapeutics began trading on the Nasdaq on January 19, 2017 under the ticker STML. At least one law firm is rumored to be investigating whether Stemline violated Federal Securities Laws. The rumored law firm’s investigation may be related to reports that the company allegedly failed to disclose that they had knowledge, on January 18, 2017, of a patient’s death who was participating in a clinical of their cancer drug.

New York, NY-based Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics. They have three drugs in development – SL-401, SL-801, and SL-701. The U.S. Food and Drug Administration granted SL-401 Breakthrough Therapy Designation based on data from this ongoing trial, which is demonstrating high overall response rates. A Phase 1 trial is open and enrolling patients with advanced solid tumors, and a Phase 1 trial in hematologic malignancies is planned for SL-801. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. A Phase 2 trial with SL-701 is currently ongoing in adult patients with second-line glioblastoma multiforme.

Stemline Therapeutucs sales have increased every year since 2013. In 2015 they reported $700k in sales. STML shares have never experienced positive EPS and for the past three years STML shares have lost between $2.15 and $2.35. STML shares are rated as a “Strong Buy” from all five analysts that cover the stock. Their consensus price target for STML is $28.50.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/2/2017
Ticker Symbol STML
Last Price a/o 12:29 PM EST  $                      6.02
Average Volume                    227,330
Market Cap (mlns)  $                  230.59
Sales (mlns) $0.90
Shares Outstanding (mlns) 23.65
Share Float (mlns) 21.29
Shortable Yes
Optionable Yes
Inside Ownership 1.70%
Short Float 6.31%
Short Interest Ratio 5.91
Quarterly Return -14.47%
YTD Return -8.88%
Year Return 110.13%

Plug Power Inc. (Nasdaq: PLUG) Hits 52-Week Low

Plug Power Inc. – Nasdaq: PLUG

Shares of Latham, NY-based Plug Power Inc. hit their 52-week lows yesterday. Shares had been above $5 in early 2014 but yesterday closed at $1.02 on heavy volume. Plug Power Inc. trades on the Nasdaq under ticker PLUG and their average daily volume is over 3.7 million shares but yesterday over 11 million shares traded hands.

The price slide in PLUG comes despite improved margins on unit sales above original estimates to such blue-chip firms such as Wal-Mart, Home Depot, and BMW. Plug Power also recently announced a partnership with two Chinese firms to serve the expanding electric car market there.

Positive earnings, however, have not yet been brought to PLUG shareholders. Despite increasing sales (103.3 million in 2015), EPS has been negative for PLUG shares for the past five years – although the losses show a narrowing trend year-on-year. In 2011, PLUG EPS showed a loss of $1.46 but by 2015 that loss had narrowed to just $0.32.

Six firms follow Plug Power. Four rate PLUG shares as a “Strong Buy”, and two rate the shares as a “Hold”. Their consensus price estimate for PLUG is $2.38.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

2/2/2017
Ticker Symbol PLUG
Last Price a/o 8:00 AM EST  $                      1.02
Average Volume                3,780,000
Market Cap (mlns)  $                  194.62
Sales (mlns) $91.80
Shares Outstanding (mlns) 190.8
Share Float (mlns) 188.63
Shortable Yes
Optionable Yes
Inside Ownership 0.70%
Short Float 17.33%
Short Interest Ratio 8.66
Quarterly Return -33.33%
YTD Return -15.00%
Year Return -38.92%